SK Biopharmaceuticals' Cenobamate and Solriamfetol Receive NMPA Approval for China Market
核心洞察
SK Biopharmaceuticals (搜索) announced that its epilepsy (搜索) drug Cenobamate and sleep disorder treatment Solriamfetol received New Drug Application approval from China's NMPA in approximately one year.
The approval targets China's epilepsy (搜索) market of over 11 million patients valued at $1.1 billion and more than 170 million patients with obstructive sleep apnea (搜索).
Development and commercialization in China will be handled by Ignis Therapeutics (搜索), a joint venture where SK Biopharmaceuticals (搜索) holds a 41% stake.
SK Biopharmaceuticals (搜索) announced on December 9th that its innovative epilepsy (搜索) drug Cenobamate and sleep disorder treatment Solriamfetol have received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA). The approval was granted approximately one year after the application was submitted in December last year, representing a notably swift review process for the Chinese pharmaceutical sector.
The application was submitted by Ignis Therapeutics (搜索), a joint venture established by SK Biopharmaceuticals (搜索) and global investment firm 6 Dimensions Capital (搜索), with SK Biopharmaceuticals holding a 41% stake. The review process is being evaluated as having proceeded swiftly, considering that new drug approval processes in China typically require various forms of supplementation and complex regulatory requirements.
Regulatory Strategy and Approval Process
The NMPA integrates and reviews various evaluation items, including clinical evidence, quality control, and manufacturing facility verification. Throughout the approval process, SK Biopharmaceuticals (搜索) and Ignis worked closely together, applying a submission strategy that simultaneously considered compliance with local Chinese guidelines through communication with the Center for Drug Evaluation (CDE) under the NMPA, as well as global clinical design strategies.
SK Biopharmaceuticals (搜索) entered into a partnership with Ignis in 2021 covering rights and approval procedures for major pipelines, including Cenobamate and Solriamfetol, in China. The two companies have been working together throughout the clinical and licensing phases since the partnership began.
Market Opportunity and Patient Population
China represents one of the world's largest markets for these therapeutic areas. The number of epilepsy (搜索) patients in China is estimated to exceed 11 million, with the market valued at $1.1 billion as of 2024. For sleep disorders, the number of patients with obstructive sleep apnea (搜索) (OSA) is estimated to be over 170 million, representing a substantial patient population that could benefit from Solriamfetol as a treatment alternative for excessive daytime sleepiness.
Commercial Strategy and Future Plans
Cenobamate and Solriamfetol are innovative drugs independently developed by SK Biopharmaceuticals (搜索), with their development and commercialization in China being carried out by Ignis. With the approval of these two new drugs, the corporate value of Ignis is expected to rise significantly, providing a foundation for further expansion of SK Biopharmaceuticals' business in China.
Ignis plans to enhance access to central nervous system disorder treatments in Greater China and continue efforts to provide new treatment options for local patients. The company aims to expedite preparations for product launch to ensure patients can benefit from these treatments as soon as possible.
Industry Impact and Executive Commentary
Aileen Long, CEO of Ignis Therapeutics (搜索), stated, "Cenobamate and Solriamfetol are innovative therapies that will bring meaningful change to patients suffering from central nervous system disorders (搜索) in China. Based on our partnership with SK Biopharmaceuticals (搜索), we will expedite preparations for product launch to ensure that patients can benefit from these treatments as soon as possible."
Lee Donghoon, CEO of SK Biopharmaceuticals (搜索), commented, "This approval in China is the result of long-term collaboration between SK Biopharmaceuticals and Ignis Therapeutics (搜索), and it marks an important milestone for the global expansion of Cenobamate and Solriamfetol. Both companies will continue to work closely together to ensure that Chinese patients can experience new treatment opportunities more quickly."